Supplement 1. Bioequivalence Studies Statistical Methods for Bioequivalence Studies:
The single dose AUC (AUC 0-last for unconjugated ezetimibe and AUC 0-∞ for atorvastatin) and C max pharmacokinetic parameters of unconjugated ezetimibe and atorvastatin in the fasted state after concomitant administration of single doses of ezetimibe and atorvastatin as separate entities or as combination tablets (FDC) will be compared using a mixed effects model appropriate for a 2-period crossover design. The separate mixed effect models will contain fixed effects for sequence, period and treatment (1.d.f.) and a random effect for subject within sequence. A log transformation will be applied to the AUC and C max data; other transformations for the pharmacokinetic parameters will be applied as appropriate.
A two-sided 90% confidence interval (CI) for the true mean difference (Treatment B vs. Treatment A) in atorvastatin AUC 0-∞ in the log scale will be calculated using the mean square error from the mixed effects model and referencing a t-distribution. These confidence limits will then be exponentiated to obtain a confidence interval for the true geometric mean ratio (GMR) for atorvastatin AUC 0-∞ (Treatment B/Treatment A). The two sided 90% confidence intervals for the unconjugated ezetimibe AUC 0-last GMR (Treatment B/A), atorvastatin C max GMR and unconjugated ezetimibe C max will be constructed in a similar manner. These 90% CIs will be then compared against the prespecified bioequivalence bounds of [0.80, 1.25].
AUC 0-t of atorvastatin and unconjugated ezetimibe will be analyzed using the same methodology as for AUC 0-∞ . Descriptive summary statistics only will be provided for the single-dose pharmacokinetic parameter T max and apparent t 1/2 of atorvastatin and unconjugated ezetimibe.
In an exploratory manner, descriptive summary statistics and the linear mixed effects model described above will also be used to compare the plasma AUC and C max of orthoand para-hydroxylated metabolites of atorvastatin as well as the plasma AUC 0-∞ and C max of total ezetimibe following the FDC and coadministration; however, no formal comparability bounds have been established for these comparisons.
Definitive Bioequivalence Study P145 -a Study to Evaluate the Definitive Bioequivalence of Ezetimibe/Atorvastatin FDC with Marketed Products
Study P145 is a pivotal study that compared the bioequivalence of the ezetimibe/atorvastatin 10/10, 10/20, and 10/80 mg combination tablets versus corresponding strengths of separate ezetimibe and atorvastatin tablets that were coadministered. The design was an open-label, randomized 3-part, 2-period, crossover definitive pharmacokinetic bioequivalence study. Two hundred eighty eight healthy subjects were assigned to Part 1, 2, or 3. Subjects were entered into the study sequentially and participated in only one part of the study (i.e., each subject participated only in Part I, Part II or Part III). Each part of the study occurred in parallel. The duration of the study was approximately 8 weeks, including the prestudy and poststudy evaluations.
The Three Parts in this study included:
Part I-single doses of ezetimibe 10 mg tablet and atorvastatin 10 mg coadministered compared to a single dose of the ezetimibe/atorvastatin 10/10 mg combination tablet Part II-single doses of ezetimibe 10 mg tablet and atorvastatin 20 mg coadministered compared to a single dose of the ezetimibe/atorvastatin 10/20 mg combination tablet Part III-single doses of ezetimibe 10 mg tablet and atorvastatin 80 mg coadministered compared to a single dose of the ezetimibe/atorvastatin 10/80 mg combination tablet.
Blood samples were collected for 96 hours following each single-dose administration of drug. Each sample was processed for the determination of the plasma concentrations of total ezetimibe, conjugated ezetimibe, atorvastatin and atorvastatin ortho and parahydroxy metabolites. There was a minimum of a 14-day washout between the two single-dose study drug administrations. 
Definitive Bioequivalence Study P183 -a Study to Evaluate the Definitive Bioequivalence of Ezetimibe/Atorvastatin FDC with Marketed Products
Study P183 is a pivotal study that compared the bioequivalence of the ezetimibe/atorvastatin 10/40 mg combination tablet versus a corresponding strength of separate ezetimibe and atorvastatin tablets that were coadministered. The design was an open-label, randomized, 2-period crossover definitive pharmacokinetic bioequivalence study. Subjects were dosed in the fasted state. Ninety six subjects entered into to the study. The duration for this study was approximately 8 weeks, including prestudy and poststudy evaluations. Blood samples were collected for 96 hours following each singledose administration of drug. Each sample was processed for the determination of the plasma concentrations of total ezetimibe, conjugated ezetimibe, atorvastatin and atorvastatin ortho and para-hydroxylated metabolites. There was a minimum of a 14-day washout between the two single-dose study drug administrations. 
